The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2019	Mar. 31, 2018	Dec. 31, 2019	Dec. 31, 2018	Nov. 28, 2018
Accrued expenses - related parties			$ 123,334
Budget reserch expense			185,000
Collection action promissory note in the principal amount	$ 250,000
Research and development expense			2,457,051	274,937
Accrued liabilities, current			1,051,961	532,790
Research and License agreement [Member]
Research and development expense			173,000	450,000
Provision for the payment to be made under agreement		$ 200,000
Sponsored Research Agreement [Member] \| From January 1, 2019 to December 31, 2021 [Member]
Amount payable for research services					$ 1,500,000
MD Anderson [Member]
Research and development expense			1,355,358	$ 0
Accrued liabilities, current			382,398
Amount payable under agreement			$ 2,038,000